|
1
|
Hu Y and Li S: Survival regulation of
leukemia stem cells. Cell Mol Life Sci. 73:1039–1050. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Linenberger ML, Hong T, Flowers D, Sievers
EL, Gooley TA, Bennett JM, Berger MS, Leopold LH, Appelbaum FR and
Bernstein ID: Multidrug-resistance phenotype and clinical responses
to gemtuzumab ozogamicin. Blood. 98:988–994. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pei S and Jordan CT: How close are we to
targeting the leukemia stem cell? Best Pract Res Clin Haematol.
25:415–418. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
She M, Niu X, Chen X, Li J, Zhou M, He Y,
Le Y and Guo K: Resistance of leukemic stem-like cells in AML cell
line KG1a to natural killer cell-mediated cytotoxicity. Cancer
Lett. 318:173–179. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fuchs D, Daniel V, Sadeghi M, Opelz G and
Naujokat C: Salinomycin overcomes ABC transporter-mediated
multidrug and apoptosis resistance in human leukemia stem cell-like
KG-1a cells. Biochem Biophys Res Commun. 394:1098–1104. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen EY, Mazure NM, Cooper JA and Giaccia
AJ: Hypoxia activates a platelet-derived growth factor
receptor/phosphatidylinositol 3-kinase/Akt pathway that results in
glycogen synthase kinase-3 inactivation. Cancer Res. 61:2429–2433.
2001.PubMed/NCBI
|
|
8
|
Zhang H, Li H, Xi HS and Li S: HIF1α is
required for survival maintenance of chronic myeloid leukemia stem
cells. Blood. 119:2595–2607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Majmundar AJ, Wong WJ and Simon MC:
Hypoxia-inducible factors and the response to hypoxic stress. Mol
Cell. 40:294–309. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hermitte F, Brunet de la Grange P, Belloc
F, Praloran V and Ivanovic Z: Very low O2 concentration (0.1%)
favors G0 return of dividing CD34+ cells. Stem Cells. 24:65–73.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rizo A, Dontje B, Vellenga E, de Haan G
and Schuringa JJ: Long-term maintenance of human hematopoietic
stem/progenitor cells by expression of BMI1. Blood. 111:2621–2630.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iwama A, Oguro H, Negishi M, Kato Y,
Morita Y, Tsukui H, Ema H, Kamijo T, Katoh-Fukui Y, Koseki H, et
al: Enhanced self-renewal of hematopoietic stem cells mediated by
the polycomb gene product Bmi-1. Immunity. 21:843–851. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lessard J and Sauvageau G: Bmi-1
determines the proliferative capacity of normal and leukaemic stem
cells. Nature. 423:255–260. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Park IK, Qian D, Kiel M, Becker MW,
Pihalja M, Weissman IL, Morrison SJ and Clarke MF: Bmi-1 is
required for maintenance of adult self-renewing haematopoietic stem
cells. Nature. 423:302–305. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Siddique HR and Saleem M: Role of BMI1, a
stem cell factor, in cancer recurrence and chemoresistance:
Preclinical and clinical evidences. Stem Cells. 30:372–378. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Meng S, Luo M, Sun H, Yu X, Shen M, Zhang
Q, Zhou R, Ju X, Tao W, Liu D, et al: Identification and
characterization of Bmi-1-responding element within the human p16
promoter. J Biol Chem. 285:33219–33229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Saudy NS, Fawzy IM, Azmy E, Goda EF, Eneen
A and Abdul SE: BMI1 gene expression in myeloid leukemias and its
impact on prognosis. Blood Cells Mol Dis. 53:194–198. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ye H, Adane B, Khan N, Sullivan T,
Minhajuddin M, Gasparetto M, Stevens B, Pei S, Balys M, Ashton JM,
et al: Leukemic stem cells evade chemotherapy by metabolic
adaptation to an adipose tissue niche. Cell Stem Cell. 19:23–37.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kreso A, van Galen P, Pedley NM,
Lima-Fernandes E, Frelin C, Davis T, Cao L, Baiazitov R, Du W,
Sydorenko N, et al: Self-renewal as a therapeutic target in human
colorectal cancer. Nat Med. 20:29–36. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nishida Y, Maeda A, Kim MJ, Cao L, Kubota
Y, Ishizawa J, AlRawi A, Kato Y, Iwama A, Fujisawa M, et al: The
novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces
p53-independent mitochondrial apoptosis in acute myeloid leukemia
progenitor cells. Blood Cancer J. 7:e5272017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bennet JM, Catovsky D, Daniel MT, Flandrin
G, Galton DA, Gralnick HR and Sultan C: Proposal for the
classification of acute leukaemias. French-American-British (FAB)
Co-Operative Group. Br J Haematol. 33:451–458. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Du R, Xia L, Ning X, Liu L, Sun W, Huang
C, Wang H and Sun S: Hypoxia-induced Bmi1 promotes renal tubular
epithelial cell-mesenchymal transition and renal fibrosis via
PI3K/Akt signal. Mol Biol Cell. 25:2650–2659. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chou TC and Talalay P: Analysis of
combined drug effects: A new look at a very old problem. Trends
Pharmacol Sci. 4:450–454. 1983. View Article : Google Scholar
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu Z, Min L, Chen D, Hao D, Duan Y, Qiu G
and Wang Y: Overexpression of BMI-1 promotes cell growth and
resistance to cisplatin treatment in osteosarcoma. PLoS One.
6:e146482011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Z, Bu X, Chen H, Wang Q and Sha W:
Bmi-1 promotes the invasion and migration of colon cancer stem
cells through the downregulation of E-cadherin. Int J Mol Med.
38:1199–1207. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li H, Song F, Chen X, Li Y, Fan J and Wu
X: Bmi-1 regulates epithelial-to-mesenchymal transition to promote
migration and invasion of breast cancer cells. Int J Clin Exp
Pathol. 7:3057–3064. 2014.PubMed/NCBI
|
|
29
|
Yuan W, Yuan Y, Zhang T and Wu S: Role of
Bmi-1 in regulation of ionizing irradiation-induced
epithelial-mesenchymal transition and migration of breast cancer
cells. PLoS One. 10:e1187992015.
|
|
30
|
Jiang L, Wu J, Yang Y, Liu L, Song L, Li J
and Li M: Bmi-1 promotes the aggressiveness of glioma via
activating the NF-kappaB/MMP-9 signaling pathway. BMC Cancer.
12:4062012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Paranjape AN, Balaji SA, Mandal T, Krushik
EV, Nagaraj P, Mukherjee G and Rangarajan A: Bmi1 regulates
self-renewal and epithelial to mesenchymal transition in breast
cancer cells through Nanog. BMC Cancer. 14:7852014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Alkema MJ, Wiegant J, Raap AK, Berns A and
van Lohuizen M: Characterization and chromosomal localization of
the human proto-oncogene BMI-1. Hum Mol Genet. 2:1597–1603. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chiba T, Miyagi S, Saraya A, Aoki R, Seki
A, Morita Y, Yonemitsu Y, Yokosuka O, Taniguchi H, Nakauchi H and
Iwama A: The polycomb gene product BMI1 contributes to the
maintenance of tumor-initiating side population cells in
hepatocellular carcinoma. Cancer Res. 68:7742–7749. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jin M, Zhang T, Liu C, Badeaux MA, Liu B,
Liu R, Jeter C, Chen X, Vlassov AV and Tang DG: miRNA-128
suppresses prostate cancer by inhibiting BMI-1 to inhibit
tumor-initiating cells. Cancer Res. 74:4183–4195. 2014. View Article : Google Scholar : PubMed/NCBI
|
